| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 topline data readout example | LYMPHIR™ (denileukin diftitox-cxdl) Recurrent or refractory gynecologic cancers, including ovarian and endometrial malignancies. | Phase 1 | — | Subscribe to access the data. | Biologics | Oncology | |
Phase 1 topline data readout example | LYMPHIR™ (denileukin diftitox-cxdl) Recurrent or refractory gynecologic cancers, including ovarian and endometrial malignancies. | Phase 1 | — | Subscribe to access the data. | Biologics | Oncology | |
Phase 1 topline data readout example | LYMPHIR™ (denileukin diftitox-cxdl) Recurrent or refractory gynecologic cancers, including ovarian and endometrial malignancies. | Phase 1 | — | Subscribe to access the data. | Biologics | Oncology |
Recent Updates
Recently added Catalysts
Citius Oncology, Inc.$0.75
+0.09 (+13.64%)
Market Cap
66.50 M
EPS
-0.46
P/E Ratio
-
Value Trade
15.00 K
SEC Financials
Q1 2026Dilution Risk
Revenue
1.67 M
R&D Expenses
1.08 M
Total Assets
100.70 M
Total Liabilities
65.43 M
Equity
35.27 M
34.77 %
Week
1.96 %
1 Month
-20.51 %
3 Month
-37.15 %
6 Month
-91.68 %
5 Year
-91.68 %
All Time
Cash Data
Cash Position
2.63 M
Monthly Burn
9.54 M
Runway
0 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
113.35 K
52 Week Range
0.49 - 2.25
% held by Insiders
71.95 %
% held by Institutions
15.32 %
Enterprise Value
64.31 M
Total Shares
92.98 M
Short %
1.36 %
Float Shares
26.91 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Citius Oncology, Inc.
94Total events
3Upcoming
32Tier-1 (high impact)
2021 – 2026Coverage
Upcoming catalysts 2
TBD
T2Debt Royalty Financing
Subscribe to view catalyst details
TBD
T2Runway Guidance Update
Subscribe to view catalyst details
Event history 2
TBD
◆Quarterly UpdateLYMPHIRApprovedCorporate
Subscribe to view catalyst details
TBD
▲Product LaunchLYMPHIRApprovedPost-Market
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
LYMPHIR | recurrent or refractory gynecologic malignancies | Phase 1 | 2026-06-01 | overall response rate: 24%; median progression free survival: 20.5 months; clinical benefit: 48% (10 of 21); objective response rate endometrial cancer: 33%; median duration of response: 21.1 months; overall median progression free survival: 5.8 months Read More | Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies Read More | |
LYMPHIR | recurrent or refractory gynecologic malignancies | Phase 1 | 2026-06-01 | overall response rate: 24%; median progression free survival: 20.5 months; clinical benefit: 48% (10 of 21); objective response rate endometrial cancer: 33%; median duration of response: 21.1 months; overall median progression free survival: 5.8 months Read More | Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies Read More | |
LYMPHIR | recurrent or refractory gynecologic malignancies | Phase 1 | 2026-06-01 | overall response rate: 24%; median progression free survival: 20.5 months; clinical benefit: 48% (10 of 21); objective response rate endometrial cancer: 33%; median duration of response: 21.1 months; overall median progression free survival: 5.8 months Read More | Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CTOR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CTOR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CTOR▲ +13.6%today
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
Citius Oncology reported significant commercial progress for its cancer treatment LYMPHIR, with a 78% increase in new institutional accounts ordering the drug. The company highlighted its expanding formulary approvals and the growing number of institutions now utilizing LYMPHIR. The treatment, indicated for relapsed or refractory cutaneous T-cell lymphoma, is gaining traction in the market with strong payer coverage.
Read more →CTORCitius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption
Citius Oncology has expanded its commercial and medical affairs teams to support the launch of LYMPHIR, a treatment for cutaneous T-cell lymphoma. The company anticipates full deployment of its expanded team by August 2026, following a recent financing round. With nearly complete payer coverage and positive physician feedback, Citius Oncology is optimistic about LYMPHIR's market adoption and growth in the latter half of 2026.
Read more →CTORCitius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
Citius Oncology presented Phase 1 clinical data for LYMPHIR in combination with pembrolizumab at the ASCO Annual Meeting. The study showed an overall response rate of 24% and a median progression-free survival of 20.5 months among patients who achieved clinical benefit. The combination demonstrated promising results in heavily pre-treated patients with recurrent gynecologic malignancies, although LYMPHIR remains investigational for these indications. Further studies are planned to explore this treatment combination more extensively.
Read more →CTORCitius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies Investigator-initiate
Citius Oncology presented promising Phase 1 clinical data for LYMPHIR in combination with pembrolizumab, targeting recurrent or refractory gynecologic malignancies. The study, conducted at the American Society of Clinical Oncology Annual Meeting, showed durable responses and tolerability among heavily pre-treated patients. Notably, 48% of patients evaluated achieved clinical benefit, including a 33% objective response rate in those with endometrial cancer. Despite these encouraging results, LYMPHIR remains investigational and not approved for such indications, emphasizing the need for further studies.
Read more →CTORCitius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
Citius Oncology announced that data from its Phase 1 combination study of LYMPHIR with pembrolizumab will be presented at the upcoming ASCO Annual Meeting. The study reported a 24% objective response rate with an average duration of response of 21.1 months among responders, alongside a favorable safety profile. The presentation reflects significant clinical interest in LYMPHIR in treating relapsed or refractory gynecologic malignancies. The study's results indicate potential benefits, although the findings are preliminary and investigational.
Read more →CTORCitius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
Citius Oncology, Inc. announced its fiscal second quarter 2026 financial results, reporting $5.6 million in net revenue driven by the launch of LYMPHIR. The company achieved broad payer coverage and significant formulary inclusion, with 83% of target accounts engaged. However, it also reported a net loss of $26.6 million, primarily due to increased administrative expenses. Citius secured up to $36.5 million in financing to support its commercial efforts.
Read more →CTORCitius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization
Citius Oncology, Inc. has secured up to $36.5 million in debt and equity capital to accelerate the commercialization of LYMPHIR, an FDA-approved therapy for cutaneous T-cell lymphoma. The funding includes a $25 million senior credit facility and $11.5 million from warrant exercises. This financial support aims to enhance the company's commercial execution and expand patient access to LYMPHIR.
Read more →CTORCitius Oncology Ships First International Order of LYMPHIR to Europe Order fulfilment expands international patient access to LYMPHIR following initial U.S. launch Distribution by regional partners through Named Patient
Citius Oncology has announced the shipment of its therapy LYMPHIR to Europe, enhancing international access following its initial U.S. launch. This distribution will be facilitated through Named Patient Programs, allowing eligible patients in various European countries to receive the treatment. The CEO emphasized the company's commitment to making LYMPHIR accessible to those in need while continuing to establish a foothold in the U.S. market, where positive adoption has reportedly been observed.
Read more →CTORCitius Oncology Ships First International Order of LYMPHIR™ to Europe Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius...
Citius Oncology has shipped its first international order of LYMPHIR to Europe, enhancing access for patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). This shipment is facilitated through Named Patient Programs, allowing physicians to request the therapy under local regulations. The company is also seeing positive adoption rates in the U.S. market since its launch.
Read more →CTOR▲ +25.7%on this news· ran to +39% by day 3
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development
Citius Oncology has reported encouraging early adoption of LYMPHIR for cutaneous T-cell lymphoma, with significant institutional uptake and broad payer coverage. The company noted a sequential growth in orders and no reimbursement denials, indicating strong market integration. Additionally, ongoing clinical studies are exploring LYMPHIR's potential in combination therapies, further supporting its role in oncology.
Read more →CTOR▼ -6.8%on this news· ran to -18% by day 3
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts
Citius Oncology will participate in the USCLC Annual Workshop 2026, focusing on cutaneous T-cell lymphoma (CTCL). The event will facilitate discussions between leading experts and Citius's team regarding the treatment landscape and clinical experiences with LYMPHIR, their recently launched therapy. The workshop aims to enhance collaboration and knowledge exchange in CTCL care.
Read more →CTORCitius Oncology Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of LYMPHIR in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers Study data from patients with relaps
Citius Oncology announced positive topline results from a Phase 1 study of LYMPHIR in combination with pembrolizumab for patients with relapsed or refractory gynecologic cancers. The study, led by the University of Pittsburgh, indicated a 24% objective response rate among evaluable patients and showcased a favorable safety profile. Dr. Myron Czuczman emphasized the encouraging safety data and sustained disease control, suggesting the therapy warrants further exploration in Phase 2 studies. Full results are expected to be presented at an international cancer conference later this year.
Read more →CTORCitius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius...
Citius Oncology announced positive topline results from a Phase 1 study evaluating LYMPHIR in combination with pembrolizumab for patients with relapsed or refractory gynecologic cancers. The study showed no unexpected safety signals and a promising objective response rate of 24%. Full results will be presented at an upcoming cancer conference, highlighting the potential of this combination therapy.
Read more →CTORCitius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma
Citius Oncology announced positive topline results from a Phase 1 trial of LYMPHIR (E7777) in patients with high-risk diffuse large B-cell lymphoma (DLBCL). The study showed an 86% overall response rate, with 57% achieving complete response. LYMPHIR was well-tolerated, and no dose-limiting toxicities were reported. The findings suggest that LYMPHIR may enhance the efficacy of CAR-T therapies.
Read more →CTORCitius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
Citius Oncology, Inc. has reported its first revenue of $3.9 million from the launch of LYMPHIR, a targeted immunotherapy for CTCL. This marks a significant transition for the company as it moves from development to commercialization. The firm is now focused on increasing physician adoption and expanding patient access, with a market potential estimated at over $400 million.
Read more →CTORCitius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar
Citius Oncology has signed an exclusive distribution agreement with Uniphar to expand access to its drug LYMPHIR in Europe. This marks the company's third international distribution partnership, aimed at improving treatment options for patients with relapsed or refractory cutaneous T-cell lymphoma. The agreement allows Uniphar to manage access and distribution in specific territories, although LYMPHIR is not yet commercially available outside the U.S.
Read more →CTOR▼ -9.8%on this news
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
Citius Oncology, Inc. reported strong financial results for FY 2025, highlighted by the U.S. launch of LYMPHIR, a targeted immunotherapy. The company secured $36 million in financing to support commercialization efforts. CEO Leonard Mazur emphasized the focus on driving adoption and expanding international access. The initial market for LYMPHIR is estimated to exceed $400 million.
Read more →CTORCitius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
Citius Oncology has successfully closed an $18 million registered direct offering and private placement, selling shares at $1.09 each. The proceeds will be utilized for the commercial launch of LYMPHIR, an FDA-approved treatment for CTCL. The company aims to capitalize on a growing market that is currently underserved.
Read more →CTORCitius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update Cancer Immunotherapy, LYMPHIR , launched in the U.S. in December 2025 Completed $36 million in strategic financings, of which
Citius Oncology, Inc. has reported its financial results for fiscal year 2025, highlighting the launch of its cancer immunotherapy LYMPHIR in the U.S. This historic launch marks the company's transition into a revenue-generating entity, supported by $36 million in strategic financings. Management notes the initial market potential for LYMPHIR exceeds $400 million, indicating significant growth opportunities. However, the company faces various challenges, including reliance on securing additional funding and navigating regulatory compliance for LYMPHIR's commercial rollout.
Read more →CTOR▲ +6.4%on this newsshared move
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules Proceeds strengthen cash position and support commercial launch of LYMPHIR , a nov
Citius Oncology has announced an $18 million fundraising effort through a registered direct offering and private placement to bolster its financial position. The funds are earmarked for the commercial launch of LYMPHIR, a new treatment for cutaneous T-cell lymphoma. The closing of the offerings is expected by December 10, 2025, pending customary conditions. LYMPHIR has gained FDA approval and addresses a significant market need for patients with relapsed or refractory CTCL.
Read more →CTOR▼ -9%on this newsshared move
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim
Citius Oncology has signed an exclusive distribution agreement with Er-Kim to expand access to LYMPHIR, a treatment for cutaneous T-cell lymphoma, in Turkey and several Gulf Cooperation Council countries. This partnership marks a significant milestone in Citius's global expansion strategy, increasing the total number of international markets for LYMPHIR to 19. The agreement allows Er-Kim to manage sales and marketing activities while Citius supplies the product.
Read more →CTOR▲ +5.6%on this news· ran to -29% by day 3shared move
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
Citius Oncology has launched LYMPHIR™, a novel immunotherapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL), approved by the FDA. The treatment shows promise with a median response time of 1.4 months and addresses a critical need in a market valued over $400 million. The company aims to ensure that LYMPHIR reaches the patients who need it, while also expanding its international access.
Read more →CTOR▲ +19.7%on this newsshared move
CORPORATE OVERVIEW NASDAQ: CTOR DECEMBER 2025 FORWARD LOOKING LANGUAGE NASDAQ: CTOR | 2 This presentation has been prepared by Citius Oncology, Inc . (the "Company") for informational purposes only and not for any other
Citius Oncology, Inc. is preparing for the commercial launch of its first product, LYMPHIR, targeting cutaneous T-cell lymphoma (CTCL). The company emphasized its operational strategies and market potential, citing a $400M+ addressable U.S. market. While the introduction of LYMPHIR promises enhanced treatment options, the company faces significant risks including funding needs and competition in the oncology space. The presentation highlights the importance of effective commercialization and ongoing regulatory compliance as crucial elements for success.
Read more →CTOR▲ +8%on this news· ran to +46% by day 3shared move
Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting
Citius Oncology announced its participation in the 67th ASH Annual Meeting, where it will exhibit its FDA-approved therapy LYMPHIR for cutaneous T-cell lymphoma. The event, taking place from December 6-9, 2025, in Orlando, Florida, will provide a platform for the company to engage with healthcare professionals and discuss the clinical benefits of LYMPHIR. The therapy aims to address an underserved market in oncology.
Read more →CTORCitius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration
Citius Oncology announced a collaboration with Verix to enhance the commercial launch of LYMPHIR™, an FDA-approved immunotherapy for cutaneous T-cell lymphoma. The integration of Verix's AI platform aims to optimize targeting and engagement with healthcare providers. LYMPHIR is expected to be commercially available in the U.S. by Q4 2025, following foundational launch activities.
Read more →CTORFORWARD LOOKING LANGUAGE This presentation has been prepared by Citius Oncology, Inc . (the "Company") for informational purposes only and not for any other purpose . Nothing contained in this presentation is, or should
Citius Oncology, Inc. is preparing for the commercial launch of its FDA-approved product LYMPHIR, aimed at treating relapsed or refractory Stage I-III cutaneous T-cell lymphoma. The company has completed key pre-commercial activities and developed a substantial inventory along with a marketing strategy to support the launch scheduled for Q4 2025. Despite the positive market potential and extensive preparations, Citius faces notable risks, including the need for additional funding and potential uncertainties impacting future results.
Read more →CTORCitius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch
Citius Oncology has announced a distribution agreement with McKesson Corporation, making it an authorized distributor for LYMPHIR, a novel immunotherapy for cutaneous T-cell lymphoma. This agreement finalizes Citius's U.S. distribution network, ensuring broad access to the therapy ahead of its planned launch in Q4 2025. The company aims to provide timely access to LYMPHIR for physicians and patients.
Read more →CTOR▼ -13.5%on this newsshared move
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™
Citius Oncology has signed an exclusive commercialization agreement with EVERSANA to support the anticipated launch of LYMPHIR™ in Q4 2025. This partnership will enhance the company's pre- and post-launch operations for its FDA-approved therapy for cutaneous T-cell lymphoma. The collaboration aims to leverage EVERSANA's expertise to ensure a successful market entry.
Read more →CTORCitius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe
Citius Oncology has established international access to its drug LYMPHIR through Named Patient Programs in Southern Europe, including Greece and Cyprus. The company has partnered with Integris Pharma to facilitate distribution, allowing eligible patients earlier access to this targeted therapy for cutaneous T-cell lymphoma. This strategic move aims to enhance awareness and clinical adoption of LYMPHIR in key markets.
Read more →CTORCitius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement
Citius Oncology has successfully closed a $9.0 million registered direct offering and concurrent private placement, involving over 5 million shares of common stock and warrants. The offering was facilitated by Maxim Group LLC and is expected to support the company's oncology product development. Citius Oncology's primary asset, LYMPHIR, has already received FDA approval for treating specific lymphoma cases.
Read more →CTORCitius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement CRANFORD, N.J.
Citius Oncology, Inc. announced a $9.0 million registered direct offering and concurrent private placement to support its oncology-focused initiatives. The company will issue over 5 million shares of common stock and warrants to a single institutional investor, with the offering expected to close by September 10, 2025. This capital infusion aims to bolster the market presence of LYMPHIR, its FDA-approved product for cutaneous T-cell lymphoma, in a growing and underserved market.
Read more →CTOR▲ +7.4%on this news· ran to +28% by day 3
Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch
Citius Oncology has announced the deployment of an advanced AI platform aimed at optimizing its sales and marketing strategies in preparation for the upcoming launch of LYMPHIR, a novel treatment for cutaneous T-cell lymphoma (CTCL). This platform will enhance targeting and engagement with healthcare providers, leveraging data analytics to identify potential candidates for treatment. Despite its promising benefits, the therapy is associated with serious side effects, including capillary leak syndrome, necessitating careful patient monitoring.
Read more →CTOR▲ +5.9%on this news
Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update
Citius Oncology, Inc. reported its fiscal third quarter 2025 financial results, highlighting a successful capital raise of $12.5 million to support the upcoming launch of LYMPHIR, a therapy for cutaneous T-cell lymphoma. The company plans to make LYMPHIR available in the fourth quarter of 2025, with distribution agreements already secured. However, the company also reported a net loss of $5.37 million for the quarter, indicating ongoing financial challenges.
Read more →CTORCitius Oncology Announces Closing of $9.0 Million Public Offering
Citius Oncology, Inc. has announced the successful closing of its public offering, raising approximately $9.0 million by selling shares and warrants. The offering facilitates financial support for the commercialization of LYMPHIR, an FDA-approved treatment for relapsed or refractory cutaneous T-cell lymphoma. The company plans to utilize these funds for milestone payments tied to licensing agreements, working capital, and general corporate purposes. This strategic financial move positions Citius Oncology to enhance market efforts and potentially contribute to healthcare in oncology.
Read more →CTORCitius Oncology Announces Pricing of $9.0 Million Public Offering CRANFORD, N.J.
Citius Oncology, Inc. announced the pricing of a public offering aimed at raising approximately $9.0 million through the sale of shares and warrants. The proceeds will primarily support the commercialization of LYMPHIR, a targeted therapy recently approved by the FDA. The offering is set to close around July 17, 2025, pending usual conditions. This development comes as Citius Oncology seeks to strengthen its position in the oncology market, which is estimated to exceed $400 million.
Read more →CTORCitius Oncology Announces Pricing of $9.0 Million Public Offering Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq:...
Citius Oncology, Inc. has announced the pricing of a public offering of 6,818,182 shares at $1.32 each, aiming to raise approximately $9.0 million. The funds will primarily support the commercialization of their FDA-approved product, LYMPHIR, and cover general corporate expenses. The offering is expected to close on July 17, 2025, pending customary conditions.
Read more →CTOR▼ -20.6%on this newsshared move
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora
Citius Oncology has entered into a distribution services agreement with Cencora to bolster the launch of its FDA-approved immunotherapy LYMPHIR for relapsed or refractory cutaneous T-cell lymphoma (CTCL). This partnership aims to enhance the company's commercial distribution capabilities and ensure product availability nationwide. Leonard Mazur, CEO of Citius Oncology, emphasized the agreement's role in building a robust launch platform that supports both immediate revenue generation and long-term shareholder value. The agreement signifies a critical step in preparing for the U.S. market introduction of LYMPHIR.
Read more →CTORCitius Oncology Anticipates Commercial Launch of LYMPHIR in 2025 CRANFORD, N.J.
Citius Oncology has announced significant preparations for the launch of LYMPHIR, an FDA-approved immunotherapy targeting relapsed or refractory cutaneous T-cell lymphoma (CTCL), expected in the second half of 2025. The company has completed commercial-scale manufacturing and is finalizing distribution partnerships to ensure broad access. A robust marketing strategy is in place, emphasizing provider education and patient support. However, potential risks such as capillary leak syndrome have been identified, which could impact patient safety and management.
Read more →CTORCitius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025 Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq:...
Citius Oncology is preparing for the commercial launch of LYMPHIR™, an FDA-approved immunotherapy for relapsed or refractory cutaneous T-cell lymphoma, expected in the second half of 2025. The company has completed manufacturing and secured distribution agreements, while engaging with key opinion leaders to refine its market strategy. Despite positive momentum, risks related to treatment side effects remain.
Read more →CTORCitius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and...
Citius Oncology, Inc. reported its fiscal second quarter 2025 results, highlighting its transition to a commercial-stage company following FDA approval of LYMPHIR. The company is focusing on disciplined capital deployment and operational execution to support its U.S. launch. However, it faces challenges with a significant net loss and the need for additional capital to sustain operations beyond May 2025.
Read more →CTORCitius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update CRANFORD, N.J.
Citius Oncology, Inc. reported its fiscal second quarter 2025 financial results, highlighting a significant transition towards a commercial-stage organization following the FDA approval of its product LYMPHIR for cutaneous T-cell lymphoma. The company emphasized its efforts in operational execution and securing additional funding to maximize shareholder value. Notably, Citius Oncology reported a net loss of $7.7 million for the quarter, necessitating additional capital to sustain operations in the near future. The company is actively engaging with strategic partners and exploring funding opportunities to enhance its financial flexibility.
Read more →CTORCitius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and...
Citius Oncology reported its fiscal first quarter 2025 results, highlighting advancements towards the launch of LYMPHIR, a targeted therapy for cutaneous T-cell lymphoma. The company engaged Jefferies as a financial advisor to explore strategic alternatives. Despite a net loss of $6.7 million, positive interim trial results were shared at a major conference, indicating LYMPHIR's potential in combination therapies.
Read more →CTORCitius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update CRANFORD, N.J.
Citius Oncology, Inc. reported its fiscal first quarter 2025 financial results, highlighting FDA approval of LYMPHIR for cutaneous T-cell lymphoma. The company aims to expedite the therapy's market launch while evaluating strategic options for growth. Financially, Citius recorded a net loss of $6.7 million, attributed to rising operating expenses due to pre-commercialization efforts. The firm also reported progress on LYMPHIR’s initiatives, including successful assignment of a reimbursement code and participation in ongoing clinical trials.
Read more →CTOR▼ -5.6%on this news
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services - Permanent J-Code (J9161) expected to be effective
Citius Pharmaceuticals and its subsidiary Citius Oncology announced that LYMPHIR has received a permanent J-code (J9161) from the Centers for Medicare & Medicaid Services, which is expected to be effective from April 1, 2025. This J-code will streamline the billing and reimbursement processes, improving access for patients with relapsed or refractory cutaneous T-cell lymphoma. LYMPHIR is an FDA-approved targeted therapy specifically indicated for adult patients who have undergone at least one prior systemic therapy. While this development is a positive step for patient access, the treatment is associated with risks such as capillary leak syndrome and visual impairments.
Read more →CTOR▼ -11.7%on this news· ran to -29% by day 3
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 CRANFORD, N.J.
Citius Pharmaceuticals and its subsidiary, Citius Oncology, have announced preparations for the commercial launch of LYMPHIR, an innovative immunotherapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL), planned for the first half of 2025. The company has made significant strides since the FDA approval of LYMPHIR in August 2024, focusing on manufacturing, marketing, and potential international licensing opportunities. Although the company expresses optimism about its market entry strategy, the drug carries risks including capillary leak syndrome, visual impairments, and hepatotoxicity.
Read more →CTOR▲ +18.5%on this newsshared move
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives CRANFORD, N.J.
Citius Oncology has appointed Jefferies LLC as its exclusive financial advisor to explore strategic alternatives that could enhance shareholder value. The company is considering various options, including partnerships and acquisitions, especially as it prepares to launch its FDA-approved cancer therapy, LYMPHIR, for cutaneous T-cell lymphoma. While this engagement signifies a commitment to strategic growth, the company has not set a specific timeline for potential decisions and acknowledges that there are no guarantees this process will lead to a successful transaction.
Read more →CTOR▲ +18.5%on this newsshared move
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives Citius Oncology, Inc. ("Citius Oncology" or "the Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius...
Citius Oncology has engaged Jefferies LLC as its exclusive financial advisor to explore strategic alternatives aimed at maximizing shareholder value. The company is considering various options, including partnerships and acquisitions, as it prepares to launch its first cancer therapy, LYMPHIR, which has recently received FDA approval for treating cutaneous T-cell lymphoma. CEO Leonard Mazur emphasized the importance of aligning opportunities with the company's long-term vision.
Read more →CTOR▲ +8.3%on this news· ran to +24% by day 3
Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update CRANFORD, N.J.
Citius Oncology, Inc. has reported its fiscal full year 2024 financial results, highlighting significant milestones, including the FDA approval of LYMPHIR for cutaneous T-cell lymphoma (CTCL). The company experienced an increase in operating expenses, leading to a net loss of $21.1 million. However, the approval is seen as a substantial advancement in treatment options for patients. Additionally, the merger that formed Citius Oncology aims to provide greater access to funding for LYMPHIR's launch and future developments.
Read more →CTOR▲ +8.3%on this news· ran to +24% by day 3
Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and...
Citius Oncology, Inc. reported its fiscal year 2024 financial results, highlighting the FDA approval of LYMPHIR for relapsed or refractory cutaneous T-cell lymphoma. The company has initiated preparations for the commercial launch of LYMPHIR, including manufacturing and marketing efforts. Despite a net loss of $21.1 million, the merger with TenX Keane strengthens its market position and funding capabilities.
Read more →CTOR▲ +6.3%on this news
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA ) and LYMPHIR in Cancer Patients with Recurrent
Citius Pharmaceuticals and Citius Oncology announced positive preliminary results from a Phase I clinical trial combining pembrolizumab (KEYTRUDA) and LYMPHIR, focusing on patients with recurrent solid tumors, particularly gynecological cancers. The trial demonstrated a 27% objective response rate and a 33% clinical benefit rate, with a median progression-free survival of 57 weeks. The treatment was well-tolerated, showing no significant immune-related adverse events, although one case of dose-limiting toxicity was reported. With three remaining patients to be enrolled, further research is planned to expand on these findings across various solid tumor types.
Read more →CTOR▲ +8.4%on this news
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology CRANFORD, N.J.
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. announced that LYMPHIR (denileukin diftitox-cxdl) has been incorporated into the NCCN Clinical Practice Guidelines in Oncology. This addition, supported by a Category 2A recommendation, highlights the drug's appropriateness for patients with relapsed or refractory Cutaneous T-cell Lymphoma (CTCL) after previous systemic therapies. The drug's approval followed promising results from a Phase 3 pivotal study, making it a unique treatment that targets the IL-2 receptor in malignant T-cells. This inclusion is expected to enhance treatment access and improve reimbursement scenarios for eligible patients.
Read more →CTORTenX Keane Acquisition Announces Contribution to Trust Account in Connection with Extension Amendment Proposal New York, NY
TenX Keane Acquisition announced a proposal to extend the deadline for completing a business combination, allowing for up to eight extensions. The sponsor, 10XYZ Holdings LP, will contribute funds to the company's trust account to support this extension if approved. Shareholders will have the opportunity to vote on this proposal in an extraordinary general meeting. However, if the extension is not approved or utilized, the company may face liquidation.
Read more →CTORCitius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc. Citius Pharmaceuticals, Inc. to receive $675 million in equi
Citius Pharmaceuticals has announced a definitive agreement to merge its wholly owned oncology subsidiary with TenX Keane Acquisition, forming Citius Oncology, Inc. Citius Pharma is expected to retain approximately 90% ownership in the new public entity and receive $675 million in equity. This strategic merger, anticipated to close in the first half of 2024, aims to enhance the development and commercialization efforts for innovative oncology therapies, notably the LYMPHIR treatment for cutaneous T-cell lymphoma. The transaction has been unanimously approved by both companies' boards of directors.
Read more →CTORTenX Keane Acquisition Announces Extension of the Deadline for an Initial Business Combination New York, NY
TenX Keane Acquisition has announced an extension of the deadline for its initial business combination from October 18, 2023, to January 18, 2024. To support this extension, the company has deposited $660,000 into its trust account, with the payment made by its sponsor, 10XYZ Holdings LP. The extension allows the company additional time to complete a merger or similar business combination.
Read more →CTORTenX Keane Acquisition Announces the Separate Trading of its Ordinary Shares and Rights Commencing on
Keane Acquisition Announces the Separate Trading of its Ordinary Shares and Rights Commencing on December 8, 2022 York, NY, December 6, 2022 (GLOBE NEWSWIRE) - TenX Keane Acquisition (the "Company") (Nasdaq: TENKU), a newly incorporated blank check company, today announced that
Read more →CTORINDEX TO FINANCIAL STATEMENTS Page Audited Financial Statements of TenX Keane Acquisition: Report of Independent Registered Public Accounting Firm (PCAOB #688) F-2 Balance Sheet as of
TO FINANCIAL STATEMENTS Page Audited Financial Statements of TenX Keane Acquisition: Report of Independent Registered Public Accounting Firm (PCAOB #688) F-2 Balance Sheet as of October 18, 2022 F-3 Notes to Financial Statement F-4 OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
Read more →CTORTenX Keane Acquisition Announces Pricing of $60 Million Initial Public Offering New York
Keane Acquisition Announces Pricing of $60 Million Initial Public Offering York, October 13, 2022 (GLOBE NEWSWIRE) - TenX Keane Acquisition (the "Company"), a newly incorporated blank check company incorporated as a Cayman Islands exempted company formed for the purpose of effe
Read more →Competitive Position
How CTOR ranks across every disease it competes inCompetitive Position is a premium feature
See how CTOR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial